DDInter1340 DDInter1492
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Omeprazole {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Ponatinib
Omeprazole {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Omeprazole {u} (Compound) causes {v} (Side Effect) Migraine
Migraine {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ponatinib
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ponatinib
Omeprazole {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Omeprazole {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) regulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Omeprazole {u} (Compound) causes {v} (Side Effect) Migraine
Migraine {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Omeprazole {u} (Compound) causes {v} (Side Effect) Hot flush
Hot flush {u} (Side Effect) is caused by {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ponatinib
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Omeprazole (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Omeprazole (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is downregulated by Ponatinib (Compound)
Omeprazole (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Ponatinib (Compound)
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Omeprazole (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Omeprazole (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) regulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Ponatinib (Compound)
Omeprazole (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Omeprazole (Compound) causes Hot flush (Side Effect) and Hot flush (Side Effect) is caused by Lansoprazole (Compound) and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib